VAX-24 is a conjugate vaccine commercialized by Vaxcyte, with a leading Phase II program in Streptococcal Pneumonia. According to Globaldata, it is involved in 6 clinical trials, of which 2 were completed, 1 is ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of VAX-24’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for VAX-24 is expected to reach an annual total of $287 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
VAX-24 Overview
VAX-24 is under development for the prevention of Streptococcus pneumonia infections including pharyngitis, impetigo, and necrotizing fasciitis and otitis media. It is a (24-valent PCV) conjugate vaccine consisting of antigens that are chemically coupled to a protein carrier. The vaccine candidate is developed based on Xpress CF platform. It is administered through intramuscular rute.
Vaxcyte Overview
Vaxcyte, formerly SutroVax, is a clinical-stage vaccine innovation company. It develops novel vaccines to prevent and treat infectious diseases. The company’s pipeline products include VAX-24, an invasive pneumococcal disease (IPD); VAX-XP, a superior conjugate vaccine against IPD; VAX-A1, group A strep infections in children; and VAX-PG, a novel protein vaccine, targeting periodontitis in adults. It utilizes a cell-free protein synthesis platform to design and produce protein carriers and antigens, the critical building blocks of vaccines. The company utilizes XpressCF platform technology to develop proteins used to produce vaccines. Vaxcyte is headquartered in Foster City, California, the US.
The operating loss of the company was US$232.3 million in FY2022, compared to an operating loss of US$103.7 million in FY2021. The net loss of the company was US$223.5 million in FY2022, compared to a net loss of US$100.1 million in FY2021.
For a complete picture of VAX-24’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
